collaboration sees strong results

During the past two weeks, Vanderbilt-Chemistry and Pharmacology, held on the Vanderbilt campus, assisted by David Weaver, Ph.D., professor of Pharmacology at Vanderbilt, and assistant professor of Pharmacology and pharmacology at the University of Kentucky, presented the joint symposium between Vanderbilt and Leipzig. The symposium offered an opportunity for students to present their work on the Vanderbilt campus, and the Leipzig faculty director of the Vanderbilt High Throughput Screening Facility, had the opportunity to study these research groups. The faculty director of the Vanderbilt High Throughput Screening Facility, had the opportunity to study these research groups at the two several years of dedicated universities.

This summer, the first federal funded research grant to Vanderbilt was provided by Andrew Beck-Stittlinger, professor of Biochemistry and Biogame, and the National Institutes of Health (NIH). The project is aimed at developing drugs for a specific type of protein known as a G protein-coupled receptor (GPCR). The grant was sponsored by the National Institutes of Health (NIH).

Recently, the university has been very competitive, for some of these projects are international collaborations, and these projects, including undergraduate and graduate students, postdoctoral fellows and faculty, have the opportunity to study the biological tests to evaluate the effectiveness of their compounds against several cancer cell lines. Wilma Neumann, a graduate student at the University of Leipzig and the lab of Dr. Lawrence Marnett, Ph.D., to evaluate the biological tests to evaluate the effectiveness of their compounds against several cancer cell lines.

The Biological tests to evaluate the effectiveness of their compounds against several cancer cell lines

Wilma Neumann, right, a visiting graduate student from Leipzig, works in the lab of Lawrence Marnett, Ph.D., with research assistant Cristina Daniel, left, and senior research specialist Brenda Crews.

"We work on GPCRs, that play a role in obesity and also cancer," Beck-Stittlinger said. "We have these receptor assays that we use to screen for new drugs that could potentially be used to treat these diseases."

One graduate student currently studying at the University of Leipzig is Wilma Neumann. "My project focuses on understanding the role of cyclooxygenase-2 (COX-2) in inflammation," she said. "COX-2 is involved in the production of prostaglandins, which are important for pain and inflammation.

"I have been working on developing new inhibitors of COX-2 that could be used as potential therapeutic agents," Neumann said. "This is a challenging and rewarding field, and I am excited to continue my research in this area.

The joint research was supported by an NIH grant, which was obtained through a collaboration with the National Institutes of Health (NIH)."